Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Enspectra Health

Explore full profile

Digital transformation in pathology by imaging cellular anatomy

Menlo Park, United StatesFounded 2012Biotech & Life Sciences
Valuation $0–100M Latest valuation · 2019
Revenue $1–10M Latest reported FY
Headcount <100 Current team size
Total funding $10–50M Disclosed equity funding
Unlock exact values This page shows ranges. Dealroom has the exact numbers for Enspectra Health and the history behind them.

About Enspectra Health

Enspectra Health, Inc. operates within the medical technology sector, focusing on the development of a novel imaging platform for non-invasive tissue evaluation. The company was incorporated in 2015 and is headquartered in Redwood City, California. Its foundation stems from the collaboration of co-founders Gabriel Sanchez, who serves as CEO, and Melina Mathur, the Chief Technology Officer.

Read full description

The founders' journey began during their time as graduate students at Stanford University, where they were part of the Biodesign Innovation Fellowship. Sanchez holds a Ph.D. in Mechanical Engineering from Stanford and an M.S. from MIT, with a background in medical device design and commercialization. Mathur also earned her Ph.D. from Stanford, specializing in Mechanical Engineering, bringing expertise in optics and device development to the venture. Their combined experience in engineering and medical technology directly informs the company's core product development.

The core of Enspectra's business is the development and commercialization of its proprietary technology, the VisiScope®. This platform is designed to provide high-resolution, cellular-level images of tissue in real-time without requiring a surgical incision. The technology utilizes a combination of advanced optics, including reflectance confocal and second-harmonic generation microscopy, to generate digital pathology images. This approach aims to create a 'virtual biopsy,' offering an alternative to the traditional excisional biopsy process, which involves tissue removal and subsequent laboratory analysis. The primary benefit for clinicians is the ability to conduct immediate evaluations of various skin conditions at the point of care, potentially accelerating diagnosis and treatment decisions. The system is intended to serve dermatologists and other physicians who manage skin conditions.

Enspectra Health has achieved significant milestones, including securing FDA 510(k) clearance for its VisiScope® imaging system in December 2023. This clearance permits the device to be marketed in the United States for imaging skin and associated adnexa. The company's business model will likely revolve around the sale of the VisiScope® device and potentially recurring revenue from software or consumables associated with the platform. The target market is the dermatology and pathology sectors, with a focus on improving diagnostic workflows and patient outcomes by reducing the need for invasive procedures.

Source: Dealroom company data

At a glance

Founded
2012
Headquarters
Menlo Park, United States
Sector
Biotech & Life Sciences

Latest news

Press, funding announcements and product moves mentioning Enspectra Health.

See all news

Investors

4 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Seed2 investors entered at this stage

  • MedTech Innovator
  • National Institutes of Health

Series A2 investors entered at this stage

  • Social Starts
  • Joyance Partners
Team profiled 4 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 2 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
1 countries with
team presence
🇺🇸 United States100%
1 country shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Enspectra Health on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Enspectra Health on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.